Next Article in Journal
Long-Term Clinical Outcomes of Ahmed Valve Implantation in Aniridic Glaucoma
Next Article in Special Issue
Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population
Previous Article in Journal
Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes
Previous Article in Special Issue
Characteristics of Sensory Neuron Dysfunction in Amyotrophic Lateral Sclerosis (ALS): Potential for ALS Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 11
Issue 11
10.3390/biomedicines11112994
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Exploring the Disease-Associated Microglia State in Amyotrophic Lateral Sclerosis

by
Carlota Jauregui
1,
Idoia Blanco-Luquin
2,
Mónica Macías
2,
Miren Roldan
2,
Cristina Caballero
3,
Inma Pagola
1,4,
Maite Mendioroz
1,2,*,† and
Ivonne Jericó
1,4,*,†
1
Neurology Department, Hospital Universitario de Navarra (HUN), IdiSNA (Navarra Institute of Health Research), 31008 Pamplona, Spain
2
Neuroepigenetics Laboratory, Navarrabiomed, Universidad Pública de Navarra (UPNA), IdiSNA (Navarra Institute of Health Research), 31008 Pamplona, Spain
3
Department of Pathology, Hospital Universitario de Navarra (HUN), IdiSNA (Navarra Institute of Health Research), 31008 Pamplona, Spain
4
Neuromuscular and Neuron Motor Diseases Research Group, Navarrabiomed, IdiSNA (Navarra Institute of Health Research), 31008 Pamplona, Spain
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomedicines 2023, 11(11), 2994; https://doi.org/10.3390/biomedicines11112994
Submission received: 22 September 2023 / Revised: 27 October 2023 / Accepted: 6 November 2023 / Published: 8 November 2023
(This article belongs to the Special Issue Mechanisms Leading to Neurodegeneration in the ALS and FTD Spectrum)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: Neuroinflammation, and specifically microglia, plays an important but not-yet well-understood role in the pathophysiology of amyotrophic lateral sclerosis (ALS), constituting a potential therapeutic target for the disease. Recent studies have described the involvement of different microglial transcriptional patterns throughout neurodegenerative processes, identifying a new state of microglia: disease-associated microglia (DAM). The aim of this study is to investigate expression patterns of microglial-related genes in ALS spinal cord. Methods: We analyzed mRNA expression levels via RT-qPCR of several microglia-related genes in their homeostatic and DAM state in postmortem tissue (anterior horn of the spinal cord) from 20 subjects with ALS-TDP43 and 19 controls donors from the Navarrabiomed Biobank. Results: The expression levels of TREM2, MS4A, CD33, APOE and TYROBP were found to be elevated in the spinal cord from ALS subjects versus controls (p-value < 0.05). However, no statistically significant gene expression differences were observed for TMEM119, SPP1 and LPL. Conclusions: This study suggests that a DAM-mediated inflammatory response is present in ALS, and TREM2 plays a significant role in immune function of microglia. It also supports the role of C33 and MS4A in the physiopathology of ALS.

1. Introduction

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of upper and lower motor neurons. Neuroinflammation is one of the pathogenic processes presumably involved in the disease, but despite being a consistent feature in ALS, its role has yet to be defined. It is important to deepen our understanding of this feature as it is an interesting therapeutic target for the disease. In addition, a complex signaling network between central nervous system (CNS) resident immune cells (microglia) and peripheral immune cells, including monocytes and T cells, has been reported in ALS and other neurodegenerative disorders [1].
Microglia are the resident immune cells of the brain and contribute to synapse formation, maintenance and immune surveillance [2]. Since its early characterization, different microglial states or patterns have been described, and there is evidence that microglia play an important role in CNS diseases through their ability to orchestrate the inflammatory response by secreting modulatory cytokines or eliminating apoptotic neurons through phagocytic and restorative functions. Apparently, microglia not only respond to disease, but also modulate its course [3].
The hypothesis of a dynamic and dichotomic polarization of microglia between a pro-inflammatory and an anti-inflammatory phenotype [4] is today rather simple and possibly does not adequately reflect the complexity of the physiological role of microglia in CNS diseases, including ALS. The characterization of microglia is currently based on the expression of specific genes that confer a transcriptional identity to these cells [5,6], which can be modified according to local or environmental signals defining different functional states of microglia [7]. Thus, microglia are a heterogeneous cell population with regional differences even under basal conditions, with the change in functional state of microglia being a dynamic process.
Disease-associated microglia (DAM) are one of the different states of microglia described in recent years. DAM has a unique transcriptional and functional signature, originally described in an animal model of Alzheimer’s disease (AD) [8]. Initially, a two-step sequential differentiation model was proposed to explain the transition from homeostatic microglia to DAM [9], in which TREM2 signaling is required for the induction of the DAM state [10]. However, other single-cell studies in human AD brains revealed a microglial transcriptional signature that partially recapitulated that of the animal model [11,12], but with notable differences [13,14,15]. It is currently controversial to consider that there is a universal signature of the microglial response to neurodegenerative damage in the human brain [16]. Other microglial states have also been described across several disease models, such as the microglial neurodegenerative phenotype (MGnD) [17] and the specific microglial signature in Parkinson’s disease (PD) [18]. To our knowledge, no microglial state has yet been described specifically in ALS.
The aim of this study is to analyze the expression of homeostatic and DAM-related genes in postmortem spinal cord tissue from ALS patients versus control donors because the knowledge of this microglial state is very limited in ALS. We have developed this study as a preliminary work to encourage further studies that will continue to explore the transcriptional identity of microglia in this disease.

2. Methods

2.1. Study Design

A case–control study was designed to compare the expression of previously described homeostatic microglia-related genes (TMEM119) [19] and genes selected following the literature review [20,21,22,23,24] that play a key role in the acquisition of DAM or MGnD status in neurodegenerative diseases (especially AD), such as TREM2, APOE, LPL, SPP1, TYROBP, CD33 and MS4A in the postmortem spinal cord of 20 ALS-TDP43 patients and 18 non-neurodegenerative control donors.

2.2. Spinal Cord Samples

The Navarrabiomed Brain Bank provided postmortem samples of fresh frozen cervical spinal cord tissue (anterior horn) from 20 patients with sporadic ALS and 18 controls without neurodegenerative disease, following the guidelines of the Spanish legislation [25] on research. 18 out of 20 patients and 16 out of 18 controls are shared with the sample set of a previous microglia-related work developed by our group [26].
The selection of patients was carried out by trained neurologists based on the inclusion criteria as follows: for the ALS group, clinically and neuropathologically diagnosed ALS with TDP-43 deposition were included [27]; for the control group, age- and sex-matched donors without neurodegenerative disease, recent vascular cerebral disease, infection or CNS injury were selected (Table 1).

2.3. Neuropathological Examination

Brain processing was performed according to the recommendation guide proposed by BrainNet Europe [28]. Formalin-fixed, paraffin-embedded tissue sections from each region of interest were sectioned at 3–5 μm and counterstained with hematoxylin-eosin for immunohistochemistry analysis with the anti-phospho TDP-43 monoclonal antibody (1:80,000, p5409/410, Cosmo Bio, Otaru, Hokkaido, Japan), mouse monoclonal antibody anti-human PHF-TAU (clone AT-8, Innogenetics, Ghent, Belgium), mouse monoclonal (S6F/3D) anti Beta-amyloid (Leica, Wetzlar, Germany) and mouse monoclonal antibody against α-synuclein (NCL-L-ASYN; Leica Biosystems, Wetzlar, Germany) and were visualized using an automated slide immunostainer (Leica Bond Max, Melbourne, VIC, Australia) with Bond Polymer Refine Detection (Leica Biosystems Newcastle Ltd., Newcastle, UK). Brain and spinal cord sections were stained with Luxol fast blue, rabbit polyclonal antibody anti-Iba1 (1:2000; Wako) and mouse monoclonal prediluted antibody anti-CD68 (1:1; Master Diagnostic) for the study of myelin pathology and inflammatory infiltration.

2.4. RNA Isolation from Frozen Spinal Cord Samples

Anterior horn total RNA was isolated from spinal cord homogenates with the RNeasy Lipid Tissue Mini kit (QIAGEN, Venlo, The Netherlands), according to the manufacturer’s recommendations. Recombinant DNase (TURBO DNA-free™ Kit, Ambion, Inc., Austin, TX, USA) was used to remove genomic DNA. The integrity of the RNA was checked in 1.25% agarose gel electrophoresis under denaturing conditions. Both RNA concentration and purity were evaluated using a NanoDrop spectrophotometer. Only those RNA samples with a minimum quality index (260 nm/280 nm absorbance ratios between 1.8 and 2.2, and 260 nm/230 nm absorbance ratios higher than 1.8) were considered in the study.

2.5. Reverse Transcription and Gene mRNA Expression Analysis via RT-qPCR

Complementary DNA (cDNA) was reverse transcribed from 1500 ng total RNA with SuperScript® III First-Strand Synthesis Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) after priming with oligo-d (T) and random primers. Real time quantitative PCR (RT-qPCR) reactions were performed in triplicate with Power SYBR Green PCR Master Mix (Invitrogen, Carlsbad, CA, USA) in a QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and then repeated within independent cDNA sets to confirm the obtained results [26]. Sequences of primer pairs were designed using Real Time PCR tool (IDT, Coralville, IA, USA) and are listed in Table 2. Relative mRNA expression levels of the studied genes in a particular sample were calculated as previously described [29] and the geometric mean of ACTB and GAPDH genes was used as reference to normalize expression values.

2.6. Statistical Data Analysis

Statistical analysis was performed with SPSS 25.0 (IBM, Inc., Chicago, IL, USA). Prior to differential analysis, continuous variables were tested for normal distribution using the one-sample Kolmogorov–Smirnov test and quantile–quantile (QQ) normal plots. Qualitative variables for each group are shown as a percentage. Quantitative variables are expressed as mean (standard deviation [SD]) when following a normal distribution. The ratio of the mean relative expression in patients to the mean relative expression in controls, or fold change (FC), was established as a measure of the magnitude of change. Differences between cases and controls were explored using Mann–Whitney U test. GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA) was used to plot the graphs.

3. Results

3.1. Sample Composition

A cohort of neuropathological characterized ALS patients (20 cases) and controls (18 cases) was selected from the Navarrabiomed Brain Bank. All ALS cases demonstrated upper and lower motor neuron degeneration accompanied by p-TDP43 neuronal inclusions. To controls selection, patients’ clinical data were evaluated to exclude subjects with a history of cancer. Those who had suffered a stroke or severe head trauma or the presence of brain anomalous proteic aggregates such as β-amyloid or Tau were also excluded.

3.2. Comparison of Gene Expression Levels

To determine whether selected genes related to homeostatic microglia (TMEM119) and DAM state (TREM2, TYROBP, APOE, MS4A, CD33, LPL and SPP1) were differentially expressed in the spinal cord of ALS patients versus controls, mRNA expression levels were measured via RT-qPCR in a cohort of 20 neuropathologically characterized ALS patients and 18 control donors.
The genes involved in facilitating the TREM2 signaling pathway (TYROBP, APOE) as well as MS4A and CD33 mRNA levels were significantly increased in ALS patients versus controls: TREM2 (fold change (FC) = 2.948; p-value < 0.0001) (Figure 1), TYROBP (FC = 1.571; p-value < 0.05) (Figure 2A), APOE (FC = 1.298; p-value < 0.05) (Figure 2B), MS4A (FC = 3.912; p-value < 0.001) (Figure 2C) and CD33 (FC = 1.608; p-value < 0.01) (Figure 2D).
However, we found no significant differences in the expression of genes related to homeostatic microglia: TMEM119 (p-value = 0.496) (Figure 3A) and genes related to the late state of DAM [8]: LPL (p-value = 0.1687) (Figure 3B) and SPP1 (p-value = 0.1333) (Figure 3C).

4. Discussion

Studies based on gene expression signatures across several diseases in human brain and animal models, have observed diverse states of microglia that play different roles throughout the different stages of neurodegenerative diseases [16]. The key feature of DAM, present at sites of neurodegeneration, is the downregulation of genes related to homeostatic microglia and the upregulation of genes involved in phagocytic, lysosomal and lipid metabolism pathways [9,30]. Moreover, the transition between homeostatic microglia and DAM is known to be mediated by the expression of TREM2 [10].
Currently, the understanding of the role of DAM in ALS is limited. In the present study, we have attempted to approach the microglial state in ALS by analyzing the expression of key genes related to the homeostatic state (TMEM119) or required for induction to the neurodegenerative DAM state according to previous descriptions (TREM2, APOE, TYROBP, CD33, MS4A, LPL, SPP1) [8].
We have showed that TMEM119 was not differentially expressed in the spinal cord of ALS patients versus controls. TMEM119 is a gene that encodes for a transmembrane protein 119 and has been proposed as a microglial marker based on its specific expression in homeostatic microglia, but not in other brain-resident cells nor in infiltrating macrophages [31]; however, its use as a consistent marker of microglia is still controversial [32]. The lack of upregulation of TMEM119 observed in our study agrees with a recent work [33] that suggests TMEM119− microglia is associated with neurodegenerative DAM in ALS, while TMEM119+ microglia may be associated with DAM-independent neurodegeneration.
Regarding the specific genes enriched in microglia that we have analyzed in this study, and that according to previous data are highly expressed in the DAM state, we observed upregulation of all of them except LPL and SPP1. Microglia are dependent on TREM2 expression to completely adopt a DAM profile [10], and interestingly, this study detected that TREM2 mRNA was upregulated in spinal cord ALS patients versus controls, which reinforces our previous observations [26] conducted on a different sample set that shared several cases and controls used in this study. TREM2 belongs to a family of transmembrane receptors of innate immune system and it is expressed in the membrane of myeloid cells, dendritic cells, osteoclasts and microglia [17]. TREM2 plays a critical role in microglial function, including phagocytosis, cytokine production and cell survival, and genetic evidence has linked TREM2 to neurodegenerative diseases including ALS, but its function in ALS pathogenesis is largely unknown [34,35,36,37,38]. Most likely, the function of microglial TREM2 may vary during the disease progression [36].
Genome-wide association studies discovered, in addition to TREM2, the overexpressed genes in the DAM state selected for this study, TYROBP [39], APOE [40,41,42,43], CD33 [44,45,46,47] and MS4A [23,45], as AD-associated microglial risk genes [48], but there is less evidence for its involvement in ALS [17,49]. Our study showed that mRNA levels of TYROBP, APOE, MS4A and CD33 were significantly increased in the spinal cord of ALS patients versus controls. APOE and TYROBP (DAP12) have been reported to act as a ligand of TREM2 by enhancing its signaling and promoting the conversion of homeostatic microglia to DAM in mouse models of ALS [17]. CD33 and MS4A are transmembrane immunoreceptors expressed on microglia. CD33 has been identified as an AD susceptibility factor [44,50] and it has been positioned as a potential therapeutic target [51]. The MS4A gene cluster is a key modulator of soluble TREM2 that has been implicated in AD and progressive supranuclear palsy (PSP) [52] pathogenesis and might provide new treatment opportunities [23,53]. To our knowledge, the contribution of CD33 and MS4A in the pathogenesis of ALS has not been previously documented.
The DAM signature described in AD disease also overexpresses LPL and SPP1 [14], genes related to late state of DAM [8]. However, our results do not show a significant overexpression of LPL or SPP1 in the late state of the disease, which could suggest that there may be an incomplete or truncated expression of the DAM program in ALS.
The SPP1 gene encodes osteopontin (OPN), a protein that has aroused interest as a therapeutic target in several immune and inflammatory diseases, including multiple sclerosis as a neurological condition [54]. OPN is a glycoprotein that is expressed in different cell types, among them microglia, which represents one of the main sources of OPN in the CNS. OPN facilitates microglia-mediated phagocytosis and repair function through different mechanisms. The role of OPN is controversial, neuroprotective or neurotoxic depending on the context and the activation state of microglia, and it seems that dysfunctional OPN could be involved in several neurodegenerative diseases including ALS [55].
Regarding LPL, it encodes lipoprotein lipase that regulates microglial lipid metabolism. It has been shown that microglia lacking LPL have altered lipid metabolism and polarize towards a pro-inflammatory state [55]. In addition, lipid accumulation of myelin debris in microglia (LDAM) impairs their phagocytic function and contributes to the progression of neurodegenerative disease [56].
We could speculate whether dysfunctional osteopontin and lipid metabolism dysfunction due to reduced expression of SPP1 and LPL, respectively, could mediate reduced the phagocytic capacity of microglia-DAM in ALS.
It is possible that the DAM state is not enough to explain the functional complexity of the role of microglia in ALS, but we found it especially noteworthy that the genes related to the early-state DAM description [7,8,9] were overexpressed, and yet, we did not find differences in the genes related to late-state DAM (SPP1 and LPL), which could suggest a partial expression of the DAM program in ALS.
Our study is limited by the small number of genes analyzed. Moreover, we have studied postmortem spinal cord tissue from patients with end-stage ALS, and it is likely that the status of microglia varies throughout the course of ALS acquiring different transcriptional profiles that understandably could not be characterized in our study. As a result, the potential use of these findings as early biomarkers of ALS is thus limited. Our results define a gene expression profile with upregulation of DAM-related genes such as TREM2, TYROBP, APOE, CD33 and MS4A and not of microglia-related homeostatic genes (TMEM119), thus supporting that DAM status plays a key role in the neuroinflammatory changes occurring in the spinal cord of ALS patients. It is necessary future studies to investigate the dynamic evolution of the microglial state in the disease, in order to identify therapeutic targets that can modify the inflammatory response at earlier stages of ALS.
In conclusion, the upregulation of TREM2, APOE, CD33, TYROBP and MS4A in the spinal cord of ALS could be potential markers of the presence of the DAM state in ALS in addition to these genes positioning themselves as potential therapeutic targets in the disease. We also showed that C33 and MS4A may play a role in the physiopathology of ALS, not previously described. Despite the limitations of this preliminary study, we hope that our results will stimulate new studies deepening the role of the DAM state in ALS.

Author Contributions

Conceptualization: M.M. (Maite Mendioroz) and I.J.; Methodology: C.J., I.B.-L. and M.M. (Mónica Macías); M.R.; Formal Analysis: I.J., C.J., I.B.-L. and M.M. (Maite Mendioroz); Data Curation: I.J., I.P. and C.C.; Writing—Original Draft Preparation: C.J. and I.J.; Supervision: M.M. (Maite Mendioroz) and I.J. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by donations from ANELA (Navarra ALS Association). Framework between ANELA and Miguel Servet Foundation/Navarrabiomed was signed on 17 December 2014.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the University Hospital of Navarra (project 61/2014).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study (Biobank donors).

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

We would like to thank all the subjects who participated in this study through their donation to the Navarrabiomed Biobank and ANELA (Navarre ALS Association) for their generous contribution. Medical writing support under the guidance of the authors was provided by Javier Arranz-Nicolás, from Medical Statistics Consulting (MSC), Valencia, Spain, in accordance with Good Publication Practice guidelines [57].

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kwon, H.S.; Koh, S.H. Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes. Transl. Neurodegener. 2020, 9, 1–12. [Google Scholar] [CrossRef] [PubMed]
  2. Woodburn, S.C.; Bollinger, J.L.; Wohleb, E.S. The semantics of microglia activation: Neuroinflammation, homeostasis, and stress. J. Neuroinflammation 2021, 18, 258. [Google Scholar] [CrossRef]
  3. Bohlen, C.J.; Friedman, B.A.; Dejanovic, B.; Sheng, M. Microglia in Brain Development, Homeostasis, and Neurodegeneration. Annu. Rev. Genet. 2019, 53, 263–288. [Google Scholar] [CrossRef] [PubMed]
  4. Eggen, B.J.L.; Raj, D.; Hanisch, U.K.; Boddeke, H.W.G.M. Microglial phenotype and adaptation. J. Neuroimmune Pharmacol. 2013, 8, 807–823. [Google Scholar] [CrossRef]
  5. Schwabenland, M.; Brück, W.; Priller, J.; Stadelmann, C.; Lassmann, H.; Prinz, M. Analyzing microglial phenotypes across neuropathologies: A practical guide. Acta Neuropathol. 2021, 142, 923–936. [Google Scholar] [CrossRef] [PubMed]
  6. Jurga, A.M.; Paleczna, M.; Kuter, K.Z. Overview of General and Discriminating Markers of Differential Microglia Phenotypes. Front. Cell Neurosci. 2020, 14, 198. [Google Scholar] [CrossRef]
  7. Xu, Y.J.; Au, N.P.B.; Ma, C.H.E. Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimer’s Disease. Front. Aging Neurosci. 2022, 14, 896852. [Google Scholar] [CrossRef]
  8. Keren-Shaul, H.; Spinrad, A.; Weiner, A.; Matcovitch-Natan, O.; Dvir-Szternfeld, R.; Ulland, T.K.; David, E.; Baruch, K.; Lara-Astaiso, D.; Toth, B.; et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell 2017, 169, 1276–1290.e17. [Google Scholar] [CrossRef]
  9. Deczkowska, A.; Keren-Shaul, H.; Weiner, A.; Colonna, M.; Schwartz, M.; Amit, I. Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell 2018, 173, 1073–1081. [Google Scholar] [CrossRef]
  10. Ulland, T.K.; Colonna, M. TREM2—A key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 2018, 14, 667–675. [Google Scholar] [CrossRef]
  11. Mathys, H.; Davila-Velderrain, J.; Peng, Z.; Gao, F.; Mohammadi, S.; Young, J.Z.; Menon, M.; He, L.; Abdurrob, F.; Jiang, X.; et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature 2019, 570, 332–337. [Google Scholar] [CrossRef] [PubMed]
  12. FFriedman, B.A.; Srinivasan, K.; Ayalon, G.; Meilandt, W.J.; Lin, H.; Huntley, M.A.; Cao, Y.; Lee, S.-H.; Haddick, P.C.; Ngu, H.; et al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer’s Disease Not Evident in Mouse Models. Cell Rep. 2018, 22, 832–847. [Google Scholar] [CrossRef] [PubMed]
  13. Zhou, Y.; Song, W.M.; Andhey, P.S.; Swain, A.; Levy, T.; Miller, K.R.; Poliani, P.L.; Cominelli, M.; Grover, S.; Gilfillan, S.; et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 2020, 26, 131–142. [Google Scholar] [CrossRef] [PubMed]
  14. Chen, Y.; Colonna, M. Microglia in Alzheimer’s disease at single-cell level. Are there common patterns in humans and mice? J. Exp. Med. 2021, 218, 1–10. [Google Scholar] [CrossRef]
  15. Srinivasan, K.; Friedman, B.A.; Etxeberria, A.; Huntley, M.A.; van der Brug, M.P.; Foreman, O.; Paw, J.S.; Modrusan, Z.; Beach, T.G.; Serrano, G.E.; et al. Alzheimer’s Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation. Cell Rep. 2020, 31, 107843. [Google Scholar] [CrossRef]
  16. Paolicelli, R.C.; Sierra, A.; Stevens, B.; Tremblay, M.-E.; Aguzzi, A.; Ajami, B.; Amit, I.; Audinat, E.; Bechmann, I.; Bennett, M.; et al. Microglia states and nomenclature: A field at its crossroads. Neuron 2022, 110, 3458–3483. [Google Scholar] [CrossRef]
  17. Krasemann, S.; Madore, C.; Cialic, R.; Baufeld, C.; Calcagno, N.; El Fatimy, R.; Beckers, L.; O’Loughlin, E.; Xu, Y.; Fanek, Z.; et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 2017, 47, 566–581.e9. [Google Scholar] [CrossRef]
  18. Smajić, S.; Prada-Medina, C.A.; Landoulsi, Z.; Ghelfi, J.; Delcambre, S.; Dietrich, C.; Jarazo, J.; Henck, J.; Balachandran, S.; Pachchek, S.; et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain 2022, 145, 964–978. [Google Scholar] [CrossRef]
  19. Butovsky, O.; Jedrychowski, M.P.; Moore, C.S.; Cialic, R.; Lanser, A.J.; Gabriely, G.; Koeglsperger, T.; Dake, B.; Wu, P.M.; E Doykan, C.; et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 2014, 17, 131–143. [Google Scholar] [CrossRef]
  20. Walker, D.G.; Whetzel, A.M.; Serrano, G.; Sue, L.I.; Beach, T.G.; Lue, L.F. Association of CD33 polymorphism rs3865444 with Alzheimer’s disease pathology and CD33 expression in human cerebral cortex. Neurobiol. Aging 2015, 36, 571–582. [Google Scholar] [CrossRef]
  21. Lambert, J.C.; Ibrahim-Verbaas, C.A.; Harold, D.; Naj, A.C.; Sims, R.; Bellenguez, C.; Jun, G. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 2013, 45, 1452–1458. [Google Scholar] [CrossRef]
  22. Pottier, C.; Ravenscroft, T.A.; Brown, P.H.; Finch, N.A.; Baker, M.; Parsons, M.; Asmann, Y.W.; Ren, Y.; Christopher, E.; Levitch, D.; et al. TYROBP genetic variants in early-onset Alzheimer’s disease. Neurobiol. Aging 2016, 48, 222.e9–222.e15. [Google Scholar] [CrossRef] [PubMed]
  23. Deming, Y.; Filipello, F.; Cignarella, F.; Cantoni, C.; Hsu, S.; Mikesell, R.; Li, Z.; Del-Aguila, J.L.; Dube, U.; Farias, F.G.; et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk. Sci. Transl. Med. 2019, 11, eaau2291. [Google Scholar] [CrossRef]
  24. Yamamoto, T.; Murayama, S.; Takao, M.; Isa, T.; Higo, N. Expression of secreted phosphoprotein 1 (osteopontin) in human sensorimotor cortex and spinal cord: Changes in patients with amyotrophic lateral sclerosis. Brain Res. 2017, 1655, 168–175. [Google Scholar] [CrossRef]
  25. García-Merino, I.M.; Consuegra, I.; Jiménez, J.L.; Muñoz-Fernández, M.Á. Specific legislation on biobanks in Spain. Biopreserv Biobank. 2015, 13, 207–211. [Google Scholar] [CrossRef] [PubMed]
  26. Jericó, I.; Vicuña-Urriza, J.; Blanco-Luquin, I.; Macias, M.; Martinez-Merino, L.; Roldán, M.; Rojas-Garcia, R.; Pagola-Lorz, I.; Carbayo, A.; De Luna, N.; et al. Profiling TREM2 expression in amyotrophic lateral sclerosis. Brain Behav. Immun. 2023, 109, 117–126. [Google Scholar] [CrossRef] [PubMed]
  27. Neumann, M.; Sampathu, D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T.; Bruce, J. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314, 130–133. [Google Scholar] [CrossRef]
  28. Bell, J.E.; Alafuzoff, I.; Al-Sarraj, S.; Arzberger, T.; Bogdanovic, N.; Budka, H.; Dexter, D.T.; Falkai, P.; Ferrer, I.; Gelpi, E.; et al. Management of a twenty-first century brain bank: Experience in the BrainNet Europe consortium. Acta Neuropathol. 2008, 115, 497–507. [Google Scholar] [CrossRef]
  29. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
  30. Mrdjen, D.; Pavlovic, A.; Hartmann, F.J.; Schreiner, B.; Utz, S.G.; Leung, B.P.; Lelios, I.; Heppner, F.L.; Kipnis, J.; Merkler, D.; et al. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 2018, 48, 380–395.e6. [Google Scholar] [CrossRef]
  31. Ruan, C.; Elyaman, W. A New Understanding of TMEM119 as a Marker of Microglia. Front. Cell Neurosci. 2022, 16, 902372. [Google Scholar] [CrossRef]
  32. Young, K.F.; Gardner, R.; Sariana, V.; Whitman, S.A.; Bartlett, M.J.; Falk, T.; Morrison, H.W. Can quantifying morphology and TMEM119 expression distinguish between microglia and infiltrating macrophages after ischemic stroke and reperfusion in male and female mice? J. Neuroinflammation. 2021, 18, 1–15. [Google Scholar] [CrossRef]
  33. Takahashi, K. Microglial heterogeneity in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2023, 82, 140–149. [Google Scholar] [CrossRef] [PubMed]
  34. Rayaprolu, S.; Mullen, B.; Baker, M.; Lynch, T.; Finger, E.; Seeley, W.W.; Hatanpaa, K.J. TREM2 in neurodegeneration: Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease. Mol. Neurodegener. 2013, 8, 1–5. [Google Scholar] [CrossRef] [PubMed]
  35. Zhou, S.L.; Tan, C.C.; Hou, X.H.; Cao, X.P.; Tan, L.; Yu, J.T. TREM2 Variants and Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. J. Alzheimer’s Dis. 2019, 68, 1171–1184. [Google Scholar] [CrossRef] [PubMed]
  36. Xie, M.; Zhao, S.; Bosco, D.B.; Nguyen, A.; Wu, L.J. Microglial TREM2 in amyotrophic lateral sclerosis. Dev. Neurobiol. 2022, 82, 125–137. [Google Scholar] [CrossRef]
  37. Jonsson, T.; Stefansson, H.; Steinberg, S.; Jonsdottir, I.; Jonsson, P.V.; Snaedal, J.; Bjornsson, S.; Huttenlocher, J.; Levey, A.I.; Lah, J.J.; et al. Variant of TREM2 associated with the risk of AD. N. Engl. J. Med. 2013, 368, 107–116. [Google Scholar] [CrossRef]
  38. Guerreiro, R.; Wojtas, A.; Bras, J.; Carrasquillo, M.; Rogaeva, E.; Majounie, E.; Cruchaga, C. TREM2 Variants in Alzheimer’s Disease. N. Engl. J. Med. 2013, 368, 117–127. [Google Scholar] [CrossRef]
  39. Haure-Mirande, J.V.; Audrain, M.; Ehrlich, M.E.; Gandy, S. Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2. Mol. Neurodegener. 2022, 17, 55. [Google Scholar] [CrossRef] [PubMed]
  40. Bertram, L.; Lange, C.; Mullin, K.; Parkinson, M.; Hsiao, M.; Hogan, M.F.; Schjeide, B.M.; Hooli, B.; DiVito, J.; Ionita, I.; et al. Genome-wide Association Analysis Reveals Putative Alzheimer’s Disease Susceptibility Loci in Addition to APOE. Am. J. Hum. Genet. 2008, 83, 623–632. [Google Scholar] [CrossRef]
  41. Bertram, L.; Tanzi, R.E. Alzheimer disease risk genes: 29 and counting. Nat. Rev. Neurol. 2019, 15, 191–192. [Google Scholar] [CrossRef] [PubMed]
  42. Rangaraju, S.; Dammer, E.B.; Raza, S.A.; Rathakrishnan, P.; Xiao, H.; Gao, T.; Duong, D.M.; Pennington, M.W.; Lah, J.J.; Seyfried, N.T.; et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease. Mol. Neurodegener. 2018, 13, 24. [Google Scholar] [CrossRef] [PubMed]
  43. Nguyen, A.T.; Wang, K.; Hu, G.; Wang, X.; Miao, Z.; Azevedo, J.A.; Suh, E.; Van Deerlin, V.M.; Choi, D.; Roeder, K.; et al. APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer’s disease. Acta Neuropathol. 2020, 140, 477–493. [Google Scholar] [CrossRef] [PubMed]
  44. Eskandari-Sedighi, G.; Jung, J.; Macauley, M.S. CD33 isoforms in microglia and Alzheimer’s disease: Friend and foe. Mol. Aspects Med. 2023, 90, 101111. [Google Scholar] [CrossRef] [PubMed]
  45. Hollingworth, P.; Harold, D.; Sims, R.; Gerrish, A.; Lambert, C.; Carrasquillo, M.M. UKPMC Funders Group Author Manuscript and CD2AP are associated with Alzheimer ’ s disease. Nat. Genet. 2011, 43, 429–435. [Google Scholar] [CrossRef]
  46. Griciuc, A.; Tanzi, R.E. The role of innate immune genes in Alzheimer’s disease. Curr. Opin. Neurol. 2021, 34, 228–236. [Google Scholar] [CrossRef]
  47. Tortora, F.; Rendina, A.; Angiolillo, A.; Di Costanzo, A.; Aniello, F.; Donizetti, A.; Febbraio, F.; Vitale, E. CD33 rs2455069 SNP: Correlation with Alzheimer’s Disease and Hypothesis of Functional Role. Int. J. Mol. Sci. 2022, 23, 3629. [Google Scholar] [CrossRef]
  48. Schwabe, T.; Srinivasan, K.; Rhinn, H. Shifting paradigms: The central role of microglia in Alzheimer’s disease. Neurobiol. Dis. 2020, 143, 104962. [Google Scholar] [CrossRef]
  49. Xie, Y.; Luo, X.; He, H.; Tang, M. Novel Insight Into the Role of Immune Dysregulation in Amyotrophic Lateral Sclerosis Based on Bioinformatic Analysis. Front. Neurosci. 2021, 15, 657465. [Google Scholar] [CrossRef]
  50. Bhattacherjee, A.; Jung, J.; Zia, S.; Ho, M.; Eskandari-Sedighi, G.; St. Laurent, C.D.; McCord, K.A.; Bains, A.; Sidhu, G.; Sarkar, S.; et al. The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia. Mol. Neurodegener. 2021, 16, 19. [Google Scholar] [CrossRef]
  51. Griciuc, A.; Federico, A.N.; Natasan, J.; Forte, A.M.; McGinty, D.; Nguyen, H.; Volak, A.; LeRoy, S.; Gandhi, S.; Lerner, E.P.; et al. Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum. Mol. Genet. 2020, 29, 2920–2935. [Google Scholar] [CrossRef]
  52. Sánchez-Ruiz de Gordoa, J.; Erro, M.E.; Vicuña-Urriza, J.; Zelaya, M.V.; Tellechea, P.; Acha, B.; Zueco, S. Microglia-Related Gene Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) Is Upregulated in the Substantia Nigra of Progressive Supranuclear Palsy. Mov. Disord. 2020, 35, 885–890. [Google Scholar] [CrossRef]
  53. Ma, J.; Yu, J.T.; Tan, L. MS4A Cluster in Alzheimer’s Disease. Mol. Neurobiol. 2015, 51, 1240–1248. [Google Scholar] [CrossRef]
  54. Hur, E.M.; Youssef, S.; Haws, M.E.; Zhang, S.Y.; Sobel, R.A.; Steinman, L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 2007, 8, 74–83. [Google Scholar] [CrossRef]
  55. Jha, A.K.; Huang, S.C.-C.; Sergushichev, A.; Lampropoulou, V.; Ivanova, Y.; Loginicheva, E.; Chmielewski, K.; Stewart, K.M.; Ashall, J.; Everts, B.; et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 2015, 42, 419–430. [Google Scholar] [CrossRef]
  56. Cunha, M.I.; Su, M.; Cantuti-Castelvetri, L.; Müller, S.A.; Schifferer, M.; Djannatian, M.; Alexopoulos, I.; van der Meer, F.; Winkler, A.; van Ham, T.J.; et al. Pro-inflammatory activation following demyelination is required for myelin clearance and oligodendrogenesis. J. Exp. Med. 2020, 217, e20191390. [Google Scholar] [CrossRef]
  57. DeTora, L.M.; Toroser, D.; Sykes, A.; Vanderlinden, C.; Plunkett, F.J.; Lane, T.; Hanekamp, E.; Dormer, L.; DiBiasi, F.; Bridges, D.; et al. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Ann. Intern. Med. 2022, 175, 1298–1304. [Google Scholar] [CrossRef]
Biomedicines 11 02994 g001
Figure 1. TREM2 levels were significantly increased in ALS patients versus controls. **** p-value < 0.0001.
Figure 1. TREM2 levels were significantly increased in ALS patients versus controls. **** p-value < 0.0001.
Biomedicines 11 02994 g001
Biomedicines 11 02994 g002
Figure 2. TYROBP (A), APOE (B), MS4A (C) and CD33 (D) levels were significantly increased in ALS patients versus controls. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.
Figure 2. TYROBP (A), APOE (B), MS4A (C) and CD33 (D) levels were significantly increased in ALS patients versus controls. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.
Biomedicines 11 02994 g002
Biomedicines 11 02994 g003
Figure 3. TMEM119 (A), LPL (B) and SPP1 (C) levels were not significant in ALS patients versus controls. ns or non-significant means p-value is >0.05.
Figure 3. TMEM119 (A), LPL (B) and SPP1 (C) levels were not significant in ALS patients versus controls. ns or non-significant means p-value is >0.05.
Biomedicines 11 02994 g003
Table 1. Data from all participants.
Table 1. Data from all participants.
ALSControlsp-Value
Spinal cord donors
n2018
Age (years) (SD) 170.1 (±13.79)73.3 (±14.29)0.491
Sex (F/M)12/86/120.093
PMI 2 (h); median (range)6.7 (3–12)6.9 (2–16)0.734
1 Standard deviation; 2 Postmortem interval.
Table 2. RT-qPCR primers used in the study.
Table 2. RT-qPCR primers used in the study.
IDAccesion Number 1Amplicon Size (bp 2)TmForward PrimerTm2 3Reverse Primer
TREM2NM_01896511661.0CTGCTCATCTTACTCTTTGTCAC62.3CAGTGCTTCATGGAGTCATAGG
TYROBPNM_00333214661.6CTGGCCGTGTACTTCCTG62GTGTTGAGGTCGCTGTAGAC
APOENM_00004114362.2TTGCTGGTCACATTCCTGG62.2AGGTAATCCCAAAAGCGACC
MS4ANM_14897514861.9TCTTGAAGGGAGAACCCAAAG62CCCCAAATTGTGTACCCGATA
CD33NM_00177213261.9TGTCAGGTGAAGTTCGCTG61.8TGCTCTGGTCTCTTGTTTCC
TMEM119NM_18172411161.7CCACTCTCGCTCCATTCG61.6CAGCAACAGAAGGATGAGGA
LPLNM_00023712961.9AAAGTGTCTCATTTGCAGAAAGG61.9CACAGAATTCACATGCCGTTC
SPP1NM_00104005814861.8GTCCCCACAGTAGACACATATG62.1TCAACTCCTCGCTTTCCATG
1 Amplified transcripts are identified according to RefSeq Accession number; 2 bp: base pair; 3 Tm: melting temperature.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Jauregui, C.; Blanco-Luquin, I.; Macías, M.; Roldan, M.; Caballero, C.; Pagola, I.; Mendioroz, M.; Jericó, I. Exploring the Disease-Associated Microglia State in Amyotrophic Lateral Sclerosis. Biomedicines 2023, 11, 2994. https://doi.org/10.3390/biomedicines11112994

AMA Style

Jauregui C, Blanco-Luquin I, Macías M, Roldan M, Caballero C, Pagola I, Mendioroz M, Jericó I. Exploring the Disease-Associated Microglia State in Amyotrophic Lateral Sclerosis. Biomedicines. 2023; 11(11):2994. https://doi.org/10.3390/biomedicines11112994

Chicago/Turabian Style

Jauregui, Carlota, Idoia Blanco-Luquin, Mónica Macías, Miren Roldan, Cristina Caballero, Inma Pagola, Maite Mendioroz, and Ivonne Jericó. 2023. "Exploring the Disease-Associated Microglia State in Amyotrophic Lateral Sclerosis" Biomedicines 11, no. 11: 2994. https://doi.org/10.3390/biomedicines11112994

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop